Correlation Between Serum and CSF Concentrations of Midazolam and 1-Hydroxy-Midazolam in Critically Ill Neurosurgical Patients

被引:0
|
作者
Farrar, Julie E. [1 ]
Stefanos, Sylvia S. [2 ]
Cava, Luis [3 ]
Kiser, Tyree H. [4 ]
Mueller, Scott W. [5 ]
Neumann, Robert [3 ]
Reynolds, Paul M. [6 ]
Sherman, Deb S. [5 ]
Maclaren, Robert [4 ]
机构
[1] Univ Tennessee, Coll Pharm, 881 Madison Ave, Memphis, TN 38163 USA
[2] Houston Methodist Hosp, Houston, TX USA
[3] Univ Colorado, Sch Med, Aurora, CO USA
[4] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
[5] Univ Colorado Hosp, Aurora, CO USA
[6] Rocky Mt Reg VA Med Ctr, Denver, CO USA
关键词
midazolam; cerebrospinal fluid; critical care; neurosurgery; PHARMACOKINETICS; SEDATION;
D O I
10.1177/10600280241271130
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Midazolam (MZ) is commonly used in critically ill neurosurgical patients. Neuro-penetration of MZ and its metabolite, 1-hydroxy-midazolam (1-OH-MZ), is not well characterized. Objective: This study evaluated correlations between serum and cerebrospinal fluid (CSF) concentrations of MZ and 1-OH-MZ and assessed implications on patient sedation. Methods: Adults in the neurosurgical intensive care unit (ICU) with external ventricular drains receiving MZ via continuous infusion were prospectively studied. Serum and CSF samples were obtained 12-24 h and 72-96 h after initiation, and concentrations were determined in duplicate by high-performance liquid chromatography with tandem mass spectrometry. Bivariate correlation analyses used Pearson coefficient. Results: A total of 31 serum and CSF samples were obtained from 18 subjects. At sampling, mean MZ infusion rate was 3.9 +/- 4.4 mg/h, and previous 12-h cumulative dose was 51.4 +/- 78.2 mg. Mean concentrations of MZ and 1-OH-MZ in serum and CSF were similar between timepoints. Similarly, ratios of 1-OH-MZ to MZ in serum and CSF remained stable over time. Serum MZ (126.2 +/- 89.3 ng/mL) showed moderate correlation (r(2) = 0.68, P < 0.001) with serum 1-OH-MZ (17.7 +/- 17.6 ng/mL) but not CSF MZ (3.9 +/- 2.5 ng/mL; r(2) = 0.24, P = 0.005) or CSF 1-OH-MZ (2.5 +/- 0.6 ng/mL; r(2) = 0.47, P = 0.30). CSF MZ did not correlate with CSF 1-OH-MZ (r(2) = 0.003, P < 0.001). Mean serum ratio of 1-OH-MZ to MZ (0.14 +/- 0.2 ng/mL) did not correlate with CSF ratio (1.06 +/- 0.83 ng/mL; r(2) = 0.06, P = 0.19). Concentrations and ratios were unrelated to MZ infusion rate or 12-h cumulative dose. Sedation was weakly correlated with CSF 1-OH-MZ, but not with serum MZ, serum 1-OH-MZ, or CSF MZ. Conclusion and Relevance: Continuous infusions of MZ result in measurable concentrations of MZ and 1-OH-MZ in CSF; however, CSF concentrations of MZ and 1-OH-MZ poorly represent serum concentrations or dosages. Accumulation of MZ and 1-OH-MZ in serum or CSF over time was not evident. Concentrations of MZ and 1-OH-MZ do not predict sedation levels, reinforcing that pharmacodynamic assessments are warranted.
引用
收藏
页码:244 / 249
页数:6
相关论文
共 50 条
  • [1] SERUM AND CSF CONCENTRATIONS OF MIDAZOLAM AND 1-HYDROXY-MIDAZOLAM IN NEUROSURGICAL PATIENTS WITH EVD
    MacLaren, Robert
    Farrar, Julie
    Stefanos, Sylvia S.
    Cava, Luis
    Kiser, Tyree
    Mueller, Scott
    Neumann, Robert
    Reynolds, Paul
    Sherman, Deb
    CRITICAL CARE MEDICINE, 2024, 52
  • [2] Investigating the Relationship Between Midazolam Serum Concentrations and Paediatric Delirium in Critically Ill Children
    Marongiu, Sabrina
    Bolhuis, Mathieu S.
    Touw, Daan J.
    Kneyber, Martin C. J.
    PEDIATRIC REPORTS, 2025, 17 (01):
  • [3] Serum midazolam concentrations in critically ill paediatric cardiac surgery patients - a pilot study
    Whitfield, KM
    Marriott, JF
    Wilson, KA
    Ralston, C
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 415P - 416P
  • [4] MIDAZOLAM INFUSIONS IN CRITICALLY ILL PATIENTS
    SHELLY, MP
    SULTAN, MA
    BODENHAM, A
    PARK, GR
    EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 1991, 8 (01) : 21 - 27
  • [5] Pharmacokinetics of midazolam in critically ill pediatric patients
    Nahara, MC
    McMorrow, J
    Jones, PR
    Anglin, D
    Rosenberg, R
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2000, 25 (3-4) : 219 - 221
  • [6] FAILURE OF CRITICALLY ILL PATIENTS TO METABOLIZE MIDAZOLAM
    SHELLY, MP
    MENDEL, L
    PARK, GR
    ANAESTHESIA, 1987, 42 (06) : 619 - 626
  • [7] Pharmacokinetics of midazolam in critically ill pediatric patients
    Milap C. Nahara
    Julie McMorrow
    Paul R. Jones
    David Anglin
    Robert Rosenberg
    European Journal of Drug Metabolism and Pharmacokinetics, 2000, 25 : 219 - 221
  • [8] Propofol versus midazolam in critically ill patients - Reply
    Chamorro, C
    deLatorre, FJ
    CRITICAL CARE MEDICINE, 1997, 25 (03) : 554 - 555
  • [9] PHARMACOKINETIC VARIABILITY OF MIDAZOLAM INFUSIONS IN CRITICALLY ILL PATIENTS
    SHAFER, A
    DOZE, VA
    WHITE, PF
    CRITICAL CARE MEDICINE, 1990, 18 (09) : 1039 - 1041
  • [10] The comparison of dexmedetomidine and midazolam for sleep in critically ill patients
    Kim, S. J.
    Lee, Y. J.
    Park, J. S.
    Cho, Y. -J.
    Yoon, H. I.
    Lee, C. -T.
    Lee, J. H.
    JOURNAL OF SLEEP RESEARCH, 2018, 27